News
MYL
15.86
0.00%
0.00
BUZZ-Regeneron closes higher after favorable US court ruling in eye drug suit
Regeneron Pharmaceuticals closes 2.88% higher at $873.98. Shares hit record high of $899.86 during regular trading. West Virginia court ruled in favor of REGN in a patent suit for its eye drug Eylea, against Mylan.
Reuters · 12/27/2023 21:40
Viatris core profit beats on generic drugs strength
Viatris core profit beats on generic drugs strength. shares up about 2% in extended trading. viatris was formed through merger of mylan and pfizer's branded drugs business. company's revenue fell about 3% to $3.94 billion in the third quarter.
Reuters · 11/07/2023 23:21
BUZZ-Viatris falls as on president Malik's retirement plan
Reuters · 10/23/2023 11:38
US Patent Office won't review two Novo Nordisk patents for Wegovy, Ozempic
Reuters · 10/02/2023 20:51
BUZZ-Viatris to divest some businesses for $3.6 bln; shares up
Reuters · 10/02/2023 11:32
Viatris beats second-quarter revenue estimates, says divestiture plans on track
Reuters · 08/07/2023 12:23
Viatris defeats IRS appeal in clash over legal fees in patent cases
Reuters · 07/27/2023 16:39
More
Webull provides a variety of real-time MYL stock news. You can receive the latest news about Mylan NL through multiple platforms. This information may help you make smarter investment decisions.
About MYL
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, brand name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. It operates through three segments on a geographic basis, North America, Europe and Rest of World. The Company's Cold-EEZE family of brands includes OTC cold remedies sold as lozenges, gummies, oral sprays, caplets, QuickMelts and oral liquid dose forms in the United States. The North America segment primarily develops, manufactures, sells and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream or ointment form. The Europe segment sells pharmaceuticals under their International Nonproprietary Name (INN), such as active pharmaceutical ingredient (API), in certain European countries. The Rest of World segment is primarily made up of its operations in India, Australia, Japan and New Zealand.